Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1150 | Daily placebo Wiki | 1.00 |
| drug621 | Bolus placebo Wiki | 1.00 |
| drug622 | Bolus vitamin D3 Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
MIHOPE is a multi-state study of home visiting programs authorized under the Maternal, Infant, and Early Childhood Home Visiting (MIECHV) program. The study is required by the federal Patient Protection and Affordable Care Act of 2010 (ACA), which created the MIECHV program. It is being conducted by MDRC under contract to the Administration for Children and Families within the US Department of Health and Human Services. In conducting the research, MDRC has subcontracted portions of the research to Mathematica Policy Research, Johns Hopkins University, Columbia University, University of Georgia, and James Bell Associates. MIHOPE is seeking to randomly assign about 4300 families nationally to home visiting services or to a comparison group that will receive referrals to other services in the community. The study is seeking to include 88 local home visiting programs (sites) that are funded through MIECHV in approximately 12 states. In Washington, the study plans to randomly assign approximately 360 families across 6 home visiting program sites. Data will be collected from families, local home visiting programs, and state and federal administrative data systems to assess the effects of the programs on family outcomes and to learn more about how the programs are run. Sites included in the evaluation will be using one of four national service models (Nurse Family Partnership, Healthy Families America, Parents as Teachers, and Early Head Start-Home Visiting Option) that states have chosen for most of their MIECHV funding. MIHOPE will inform the federal government about the effectiveness of the MIECHV program in its first few years of operation, and it will provide information to help states develop and strengthen home visiting programs in the future. Research findings will be disseminated through a report to Congress in 2015; reports on program impacts, implementation, and on the relationship between program features and program impacts; journal articles; and practitioner briefs.
Description: Mother has had one or more pregnancies since study entry
Measure: New pregnancy after study entry Time: through child's 15th monthDescription: Whether the child has had an injury or ingestion that lead to a health encounter.
Measure: Any health encounter for injury or ingestion Time: through child's 15th monthDescription: Number of well-child visits
Measure: Number of well-child visits Time: through child's 15th monthDescription: Parental supportiveness measured from Three Bags interaction of parent with child
Measure: Parental supportiveness Time: at child's 15th monthDescription: Quality of home environment measured using the IT-HOME
Measure: Quality of home environment Time: at child's 15th monthDescription: Whether the child has health insurance coverage
Measure: Child has health insurance coverage Time: at child's 15th monthDescription: Behavior problems total score from the BITSEA parent report
Measure: Behavior problems Time: at child's 15th monthDescription: Whether parent reports indicate child has been victim of minor physical assault
Measure: Frequency of minor physical assault of child Time: through child's 15th monthDescription: Whether parent reports indicate child has been victim of psychological aggression
Measure: Frequency of psychological aggression Time: through the child's 15th monthDescription: Whether child has visited the ED
Measure: Any child ED use Time: through child's 15th monthDescription: Whether child has language skills in the normal range, as measured through a direct assessment
Measure: Language skills in the normal range Time: at child's 15th monthDescription: Whether parent is receiving education or training
Measure: Parent receiving education or training Time: at child's 15th monthDescription: Mother reports having given birth to one or more children after study entry
Measure: New birth after study entry Time: When focal child is 2.5 years old and when focal child is 3.5 years oldDescription: Whether mother reports depressive symptoms based on the CESD-10 scale
Measure: Maternal depressive symptoms Time: When focal child is 2.5 years old and when focal child is 3.5 years oldDescription: Whether mother reported her health was fair or poor
Measure: Health status of mother is rated "fair" or "poor" Time: When focal child is 2.5 years old and when focal child is 3.5 years oldDescription: Mother's report of number of visits to the ED for the child for accidents or injuries
Measure: Number of child emergency department visits for accident or injury Time: From age 15 months to 2.5 years for the child, and from 2.5 years to 3.5 yearsDescription: Whether the mother indicates she is currently receiving training or education
Measure: Mother is pursuing education or training Time: When focal child is 2.5 years old and when focal child is 3.5 years oldDescription: Mother's report of yelling at the child as a disciplinary practice
Measure: Use of yelling as a disciplinary practice Time: When focal child is 2.5 years old and when focal child is 3.5 years oldAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports